Quantcast

Posts related to ‘Pharmaceuticals’

One Big Disbelief of an Amylin Buyout… Worth Only $12 Per Share? (AMLN, BMY, MRK, AZN, SNY, PFE, NVO)

Posted: April 27, 2012 at 9:15 am

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is supposed to be acquired by a larger drug company.  It is one of the biggest public merger rumors out there. At least that is the belief ...
Read Full Story »

J&J Joins Dividend Hike One-Up Game (JNJ, PFE, MRK)

Posted: April 26, 2012 at 11:13 am

How many DJIA components can raise their dividend in one week?  Johnson & Johnson (NYSE: JNJ) answered that question as "Who knows, but we can make it one more!"  J&J ...
Read Full Story »

Amylin Gets Carl Icahn Off Its Neck! (AMLN, IEP)

Posted: April 25, 2012 at 2:26 pm

Amylin Pharmaceuticals, Inc. (AMLN) is supposed to be getting a takeover offer soon, or at least it is expected to receive or disclose several possible bids soon.  Now the company ...
Read Full Story »

What’s A Better Buyout: Ardea or Amylin? (RDEA, AMLN, AZN, BMY, MRK)

Posted: April 23, 2012 at 2:54 pm

Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion to acquire the company.  With another small-cap to mid-cap biotech and ...
Read Full Story »

Amylin Seeks a Buyer (AMLN, CS, GS, BMY, SNY, LLY, AZN, MRK)

Posted: April 23, 2012 at 7:59 am

Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer ...
Read Full Story »

VioPharma Runs Into FDA & FTC Troubles Over Staph Drug (VPHM)

Posted: April 10, 2012 at 8:35 am

ViroPharma Incorporated (NASDAQ: VPHM) is getting crushed on news that the Food & Drug Administration has denied the petition filed by ViroPharma on March 17, 2006 related to the FDA's ...
Read Full Story »

Drug Maker Prices Secondary Offering (GALE)

Posted: April 5, 2012 at 10:11 am

Biotech firm Galena Biopharma Inc. (NASDAQ: GALE) this morning priced a secondary offering of 8.5 million shares at $1.50/share, a discount of nearly 20% to last night’s closing price of ...
Read Full Story »

Drug Company Buyout Follows Failed Drug Trial (SPPI, ALTH)

Posted: April 5, 2012 at 9:15 am

Spectrum Phamaceuticals Inc. (NASDAQ: SPPI) has agreed to acquire rival drug firm Allos Therapeutics Inc. (NASDAQ: ALTH) for $1.82 in cash and one Contingent Value Right (CVR), in a deal ...
Read Full Story »

Theravance Jumps on Glaxo Investment (THRX, GSK)

Posted: April 2, 2012 at 12:23 pm

Theravance Inc. (NASDAQ: THRX) got a big boost today from a purchase of 10 million additional shares by GlaxoSmithKline plc (NYSE: GSK) at a 7.5% premium to a volume-weighted average ...
Read Full Story »

Keryx Drug Fails Test, Shares Plunge (KERX)

Posted: April 2, 2012 at 7:54 am

Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) this morning announced that its colorectal cancer treatment did no better than placebo in a Phase 3 trial. The company said it will evaluate whether ...
Read Full Story »

Vermillion Scores Patent on Cancer Test (VRML)

Posted: March 28, 2012 at 10:10 am

Shares of diagnostics company Vermillion Inc. (NASDAQ: VRML) have jumped more than 20% this morning following the company’s announcement of a patent approval for another of its biomarkers used to ...
Read Full Story »

The Inevitable Amylin Buyout (AMLN, BMY, LLY, ALKS)

Posted: March 28, 2012 at 9:52 am

If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN).  News from Bloomberg is out that the company has rejected an ...
Read Full Story »

Targacept Gets Mixed Results on Drug Trials (TRGT, AZN)

Posted: March 27, 2012 at 9:41 am

Development stage drug maker Targacept Inc. (NASDAQ: TRGT) is having its troubles these days. Earlier this month the company said it would not seek US Food and Drug Administration approval ...
Read Full Story »

Bausch + Lomb Nabs ISTA (ISTA, VRX)

Posted: March 27, 2012 at 8:52 am

Privately held Bausch + Lomb Inc. has made ISTA Pharmaceuticals Inc. (NASDAQ: ISTA) an offer it can’t refuse. The eye care company owned by private equity firm Warburg Pincus will ...
Read Full Story »

Teva Launches Generic Seroquel on First Day of Patent Loss (TEVA, AZN)

Posted: March 26, 2012 at 2:29 pm

We noted earlier today that AstraZeneca plc (NYSE: AZN) had lost a patent ruling and that the company’s anti-pyschotic drug Seroquel lost its patent protection today. That’s all it took ...
Read Full Story »